JAC Advance Access published online on March 10, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki074
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington St, Winnipeg, Manitoba, Canada, R3E 3R2
* To whom correspondence should be addressed. Objectives: To characterize the mechanism of cefoxitin resistance in clinical isolate Escherichia coli N99-0001. Methods: Plasmid analysis, PCR for Results: Analysis of the ampC promoter region of E. coli N99-0001 revealed a T Conclusions: Cefoxitin resistance in E. coli N99-0001 was due to overexpression of ampC caused by an increase in promoter strength.
Received December 9, 2004
Revised January 25, 2005
Accepted January 26, 2005
Brief report
Increase in ampC promoter strength due to mutations and deletion of the attenuator in a clinical isolate of cefoxitin-resistant Escherichia coli as determined by RT-PCR
2 Cadham Provincial Laboratory, Winnipeg, Manitoba, Canada
Michael R. Mulvey, E-mail: Michael_mulvey{at}phac-aspc.gc.ca
![]()
Abstract
-lactamases, and sequencing of the ampC genes was carried out. An RT-PCR method was developed to determine relative ampC expression.
A mutation at -32, a C
A mutation at -11, an insertion of a T between -20 and -21, and a 28 bp deletion including the entire attenuator. RT-PCR showed that ampC was expressed 140-fold higher in E. coli N99-0001 than in E. coli ATCC 25922.![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. F. Mataseje, N. Neumann, B. Crago, P. Baudry, G. G. Zhanel, M. Louie, M. R. Mulvey, and and the ARO Water Study Group Characterization of Cefoxitin-Resistant Escherichia coli Isolates from Recreational Beaches and Private Drinking Water in Canada between 2004 and 2006 Antimicrob. Agents Chemother., July 1, 2009; 53(7): 3126 - 3130. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Haldorsen, B. Aasnaes, K. H. Dahl, A.-M. Hanssen, G. S. Simonsen, T. R. Walsh, A. Sundsfjord, and E. W. Lundblad The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1-like ampC element or hyperproduction of the endogenous AmpC J. Antimicrob. Chemother., October 1, 2008; 62(4): 694 - 702. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Smet, A. Martel, D. Persoons, J. Dewulf, M. Heyndrickx, B. Catry, L. Herman, F. Haesebrouck, and P. Butaye Diversity of Extended-Spectrum {beta}-Lactamases and Class C {beta}-Lactamases among Cloacal Escherichia coli Isolates in Belgian Broiler Farms Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1238 - 1243. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kaneko, Y. Sato, S.-k. Tokunaga, S.-k. Tamaki, R. Okamoto, and M. Inoue AmpC {beta}-lactamase-mediated cefpodoxime-resistant Escherichia coli isolated from faecal samples of healthy volunteers J. Antimicrob. Chemother., February 1, 2006; 57(2): 369 - 371. [Full Text] [PDF] |
||||
![]() |
C. Bauvois, A. S. Ibuka, A. Celso, J. Alba, Y. Ishii, J.-M. Frere, and M. Galleni Kinetic Properties of Four Plasmid-Mediated AmpC {beta}-Lactamases Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4240 - 4246. [Abstract] [Full Text] [PDF] |
||||

